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Experiments in animals suggest that the neuropeptide oxytocin
acts as an anorexigenic signal in the central nervous control of
food intake. In humans, however, research has almost exclusively
focused on the involvement of oxytocin in the regulation of social
behavior. We investigated the effect of intranasal oxytocin on
ingestion and metabolic function in healthy men. Food intake in
the fasted state was examined 45 min after neuropeptide
administration, followed by the assessment of olfaction and
reward-driven snack intake in the absence of hunger. Energy
expenditure was registered by indirect calorimetry, and blood
was repeatedly sampled to determine concentrations of blood
glucose and hormones. Oxytocin markedly reduced snack con-
sumption, restraining, in particular, the intake of chocolate
cookies by 25%. Oxytocin, moreover, attenuated basal and post-
prandial levels of adrenocorticotropic hormone and cortisol and
curbed the meal-related rise in plasma glucose. Energy expendi-
ture and hunger-driven food intake as well as olfactory function
were not affected. Our results indicate that oxytocin, beyond its
role in social bonding, regulates nonhomeostatic, reward-related
energy intake, hypothalamic-pituitary-adrenal axis activity, and the
glucoregulatory response to food intake in humans. These effects
can be assumed to converge with the psychosocial function of
oxytocin and imply possible applications in the treatment of
metabolic disorders. Diabetes 62:3418–3425, 2013
The hypothalamic nonapeptide oxytocin is re-leased into the circulation by axonal terminals inthe posterior pituitary and, moreover, acts di-rectly on central nervous receptors. Oxytocin,
which has been highly preserved during mammalian
evolution, regulates physiological functions related to
reproduction and mother-infant interaction, such as lac-
tation, and in recent years, has been shown to modulate
afﬁliative behavior (1). Research in humans has almost
exclusively focused on the role of oxytocin in the regula-
tion of prosocial behavior, including trust, attachment, and
sexual behavior (2–5), largely ignoring potential effects of
the neuropeptide on ingestive behavior and metabolism. In
fact, evidence from rodent studies indicates that the neu-
ropeptide acts as a strong inhibitor of food intake and
affects energy expenditure and glucose homeostasis (6–9).
Oxytocinergic neurons in the hypothalamic paraventricular
nucleus are assumed to mediate the food intake–limiting
effect of leptin, an adipokine that provides the brain with
negative feedback on body fat stores and sensitizes caudal
brainstem nuclei to satiety factors such as cholecystokinin
(10). Hypothalamic oxytocin signaling, moreover, medi-
ates anorexigenic effects of the satiety factor nesfatin-1 in
a leptin-independent manner (11). Importantly, oxytocin
reduces food intake not only in normal-weight rodents but
also in animals with diet-induced obesity (8,12,13), so oxy-
tocinergic pathways might be a promising target of clinical
interventions in obese patients.
The direct manipulation of neuropeptidergic central
nervous signaling pathways can be achieved via the in-
tranasal administration of peptides, which is known to
bypass the blood–brain barrier and result in signiﬁcant
cerebrospinal ﬂuid elevations in substance levels within 40
min, without the need for systemic infusion (14,15). This
approach has been validated, among others, for vaso-
pressin, a close homolog of oxytocin (14), and intranasal
oxytocin administration has been shown to reliably mod-
ulate neuropsychological functions in a series of studies
(2–5) in the absence of relevant side effects (16). Sur-
prisingly, however, the effect of intranasal oxytocin on
energy metabolism, including ingestive behavior, has not
been investigated in humans so far. The assessment of re-
spective effects of intravenous oxytocin (17) is hampered
because peripheral oxytocin is not readily transported
across the blood–brain barrier (18).
In the present experiments, we studied the contribution
of oxytocin signaling to the control of ingestive behavior
and energy expenditure in normal-weight, healthy men,
with a particular view to endocrine regulators of metabolism,
such as ghrelin and insulin, as well as hypothalamic-pituitary-
adrenal (HPA) axis secretory activity. Ingestive behavior is
not only regulated homeostatically (i.e., by central nervous
pathways that respond to energy depletion) but also by
nonhomeostatic brain circuits that process the reward-
related, “hedonic” qualities of food intake (19). Therefore,
we applied a twofold assessment of food intake that relied,
on the one hand, on a large breakfast buffet after an over-
night fast to investigate homeostatic, primarily hunger-
driven energy intake (20–22), and on the other hand, on a
collection of snacks of varying palatability offered after
breakfast intake for the measurement of reward-driven
food intake (22–24).
RESEARCH DESIGN AND METHODS
Subjects. The study participants were 20 healthy, male, nonsmokers who were
free of medication (aged 26.3 6 0.89 years; BMI 22.66 6 0.36 kg/m2). All rel-
evant illness was excluded by medical history and clinical examination.
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Subjects were kept unaware of the hypothesized treatment effects on food
intake and were informed that the experiments concerned the effect of oxy-
tocin on taste preferences and energy expenditure. Participants gave written
informed consent to the study that conformed to the Declaration of Helsinki
and was approved by the local ethics committee.
Design and procedure. Experiments were carried out in a double-blind, cross-
over, within-subject comparison. Each subject participated in two experimental
sessions, oxytocin and placebo. The order of conditions was balanced across
subjects, and the two sessions were spaced at least 10 days apart. Participants
were instructed to abstain from the intake of food and of caffeinated and al-
coholic beverages after 2000 h on the day preceding each session.
After the subject’s arrival at the laboratory at ;0800 h, a venous cannula
was inserted into the subject’s nondominant arm to enable drawing of venous
blood (see Fig. 1 for the experimental procedure). Thereafter, blood was
sampled for baseline assessments of hormonal parameters. Mood, hunger, and
thirst were rated, and energy expenditure was measured by indirect calo-
rimetry. At 0942 h, six 0.1-mL puffs (three per nostril) of oxytocin (Syntocinon;
Deﬁante Farmaceutica, Funchal Madeira, Portugal) and vehicle, respectively,
were intranasally administered at 30-second intervals, amounting to a total
dose of 24 IU oxytocin (0.6 mL).
Forty-ﬁve minutes after administration, subjects were presented with
a breakfast buffet from 1030–1100 h. Olfactory function was tested at 1155 h.
Mood, hunger, and thirst were rated, and energy expenditure was measured by
indirect calorimetry after substance administration and after the breakfast
buffet (Fig. 1). At 1240 h, casual snack intake was assessed under the pretext
of a snack taste test. At 60 min before and at 35 and 120 min after substance
administration, subjects rated the experimenter’s general trustworthiness.
Heart rate and blood pressure were monitored throughout the experiment. At
the end of the experiments, subjects were asked to indicate their account of
the study purpose.
Assessments of food intake, hunger, thirst, mood, and olfaction. The
free-choice ad libitum test buffet comprised a variety of food choices (Table 1)
from which subjects could eat undisturbed for 30 min. They were not aware
that their food intake was measured by weighing buffet components before
and after breakfast. This procedure has been repeatedly shown to enable the
precise assessment of primarily hunger-driven food intake in the fasted state
(20–22). Reward-related eating in the absence of hunger was assessed using
a snack test validated in a series of previous studies (22–24). Subjects were
presented with three types of snacks of different taste but comparable calorie
content and macronutrient composition (Table 2), each on a separate plate,
and labeled snack A, B, and C, respectively. The three types were, “TUC
Cracker Classic” (salty taste; Griesson-de Beukelaer, Polch, Germany), “Rice
Wafﬂes” (bland taste; Continental Bakeries B.V., Dordrecht, The Netherlands),
and “Double Chocolate Cookies” (sweet taste; EDEKA, Hamburg, Germany).
For each variety, 15 snacks broken into bite size pieces were provided,
allowing for a considerable amount to be eaten without the plates appearing
empty to ensure that participants would not restrict snack intake based on
whether the experimenter could see how much had been consumed. The
participant was instructed to taste and rate each type of snack on a visual
analog scale (VAS) anchored by 0 (not at all) and 10 cm (very palatable/sweet/
salty). The importance of giving accurate ratings was emphasized, and sub-
jects were informed that during and after completion of the rating task they
could eat as many snacks as they liked because any remaining food would be
discarded, and were left alone for 10 min. Snack intake was covertly measured
by weighing the snacks before and after the test.
Hunger, thirst, and also trustworthiness of the experimenter were rated on
VAS (0–100 mm). Self-reported mood was assessed with 5-point scales cov-
ering the categories good/bad mood, alertness/sleepiness, and calmness/
agitation (Der mehrdimensionale Beﬁndlichkeitsfragebogen [25]). Olfac-
tory function was tested 60 min after the test buffet with the validated Snifﬁn’
Sticks commercial test kit (Burghart Elektro- und Feinmechanik GmbH, We-
del, Germany) that allows for the separate characterization of the three
dimensions of olfactory threshold, discrimination, and identiﬁcation (26).
Measurement of energy expenditure, plasma glucose, and hormonal
parameters. Energy expenditure (expressed as kcal/day) was measured via
indirect calorimetry using a ventilated-hood system (Deltatrac II, MBM-200
Metabolic Monitor; Datex-Engström Deutschland, Achim, Germany). Before
each use, the device was calibrated with Quick Cale calibration gas to 5% CO2
and 95% O2. Calorimetric measurements took place from 0900 to 0930 h
(baseline), immediately after intranasal substance administration from 0945 to
1015 h to assess effects of intranasal oxytocin alone, and again between 1105
and 1145 h (i.e., after the ad libitum test buffet) to register postprandial energy
expenditure. The rise in energy expenditure between the fasting state (base-
line) and the postprandial state reﬂects diet-induced thermogenesis (i.e., the
energy that is emitted as heat during metabolization of food) and thus does not
contribute to the production of ATP (27).
Blood samples for the assessment of serum insulin, C-peptide, cortisol,
growth hormone, leptin, plasma glucose, glucagon, total and active glucagon-
like peptide-1 (GLP-1), adrenocorticotropic hormone (ACTH), and total ghrelin
were centrifuged, and samples were stored at 280°C. Blood for the mea-
surement of glucagon and total/active GLP-1 was pretreated with aprotinin
(370 kIU/mL; Roth GmbH, Karlsruhe, Germany) and dipeptidyl peptidase-IV–
inhibitor blocking reagent (50 mmol/L; Millipore, St. Charles, MO), re-
spectively. Routine assays were used to determine concentrations of plasma
glucose measured in ﬂuoride plasma according to the hexokinase method
(Aeroset; Abbott Diagnostics, North Chicago, IL), insulin, C-peptide, ACTH,
cortisol (all Immulite, DPC, Los Angeles, CA), total ghrelin, leptin, total and
active GLP-1 (all RIA, Millipore, Billerica, MA), and glucagon (RIA, IBL In-
ternational, Hamburg, Germany).
Statistical analysis. Analyses were based on ANOVA with the within-subject
factors “treatment,” “time,” “nutrient,” and “snack type,” as appropriate.
Degrees of freedom were corrected using the Greenhouse-Geisser procedure.
Signiﬁcant ANOVA effects were speciﬁed by pairwise t tests. For blood
parameters and energy expenditure, baseline adjustment was achieved by
subtracting individual baseline values from individual postintervention mea-
surements. Supplementary analyses of snack intake and blood glucose peak
values relied on ANCOVA, including as covariates the differences between
conditions in overall calorie and carbohydrate consumption during breakfast
intake. All data are presented as means 6 SEM. A P value , 0.05 was con-
sidered signiﬁcant.
RESULTS
Oxytocin inhibits reward- but not hunger-driven
eating. Oxytocin administration did not affect food in-
take from the breakfast buffet in the fasted state. Overall
food consumption and the proportion of ingested macro-
nutrients were nearly identical between conditions (all P .
0.6; Table 3). Accordingly, hunger ratings (P . 0.2, two-
sided t test for baseline values; Fig. 2A) were not altered by
oxytocin (P . 0.9) and fell to comparably low values of
;15% of the maximal score during breakfast (P . 0.2;
F2,36 = 74.91, P , 0.0001 for time; P . 0.5 for treatment
effects), indicating that subjects in both conditions were
satiated by breakfast intake. Thirst ratings and self-rated
mood were likewise unaffected by oxytocin (P . 0.12 for
all comparisons).
In the snack test during the postprandial period, oxy-
tocin compared with placebo induced a reduction in total
snack intake (F1,19 = 5.5, P , 0.03 for treatment; Fig. 2B)
FIG. 1. Experimental procedure. After baseline assessments of blood
parameters, psychological variables and energy expenditure, healthy
young men were intranasally administered oxytocin (24 IU) and pla-
cebo, respectively, at 0942 h (nose symbol). At 1030 h, 45 min after
substance administration, subjects were allowed to eat ad libitum from
a free-choice test buffet for 30 min. At ;60 min after termination of the
buffet, at 1155 h, olfactory function was assessed, and at 1240 h, 100
min after the end of the buffet meal, snack intake was measured under
the pretext of a taste-rating task. Throughout the session, mood, hun-
ger, and thirst were assessed, and blood samples were taken (▼).
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that was driven by a decrease in chocolate cookie con-
sumption by 25% (P , 0.01, two-sided t test; Fig. 2C and
Table 4). These effects remained signiﬁcant when corrected
for overall calorie and carbohydrate consumption during
the preceding test buffet (both P , 0.04 for treatment; P ,
0.007 for the difference in chocolate cookie consumption).
Across conditions, intake of chocolate cookies by far
exceeded that of the remaining snacks (F1,23 = 9.50, P ,
0.004 for snack type). Also, sweetness and saltiness ratings
were highest for chocolate cookies and salt crackers, re-
spectively (F2,31 = 342.28, P , 0.0001; and F2,36 = 112.18,
P , 0.0001, for snack type). Oxytocin did not affect ratings
for chocolate cookies and salt crackers (P . 0.3) and even
slightly increased rated palatability of rice wafﬂes (P, 0.05;
Table 4). In the olfactory task, no treatment effects on
perceptual thresholds (P . 0.4), olfactory discrimination
(P . 0.6), and olfactory identiﬁcation (P . 0.2) emerged,
and oxytocin administration did not affect the trustworthi-
ness of the experimenter as perceived by the participants
(P . 0.6).
Energy expenditure is not acutely affected by
oxytocin administration. Energy expenditure assessed
by indirect calorimetry was comparable between the pla-
cebo and the oxytocin condition during the entire experi-
mental period (F1,19 = 2.12, P . 0.16 for treatment 3 time;
F1,19 = 0.10, P . 0.75 for treatment), averaging 1609 6 41
vs. 1651 6 37 kcal/day (P . 0.12) under baseline fasting
conditions, 1615 6 21 vs. 1633 6 13 kcal/day (P . 0.46)
after placebo and oxytocin administration, respectively,
and 2021 6 48 vs. 1985 6 34 kcal/day (P . 0.4) after
breakfast intake, with the latter values reﬂecting diet-
induced thermogenesis ;23% above preprandial baseline
measurements (F1,19 = 145.24, P , 0.0001 for time).
Oxytocin reduces HPA axis activity as well as
norepinephrine concentrations and blunts the glucose
response to food intake. During baseline, none of the
blood parameters, including blood glucose, differed between
conditions (all P . 0.18). Oxytocin exerted a sustained
suppressive effect on HPA axis activity, reducing serum
ACTH and plasma cortisol concentrations during the entire
postadministration period (F1,18 = 4.67, P , 0.05 and F1,18 =
5.15, P , 0.04, respectively, for treatment; Fig. 2D and E).
The effect on cortisol was particularly pronounced before
breakfast intake (F2,35 = 4.82, P, 0.02 for treatment3 time).
In parallel, preprandial circulating concentrations of norepi-
nephrine were reduced by oxytocin treatment (F1,19 = 5.41,
P = 0.03 for treatment 3 time; Fig. 3F). Supplementary
analyses indicated that the oxytocin-induced decreases in
cortisol concentrations (area under the curve with respect to
increase 0930–1145 h) and chocolate cookie intake were
TABLE 1
Composition of the test buffet
Food Weight (g) Energy (kcal) Carbohydrate (g) Fat (g) Protein (g)
Neutral
Whole wheat bread 165 360 71 2.3 12
Wheat rolls 240 275 122.4 3.4 6.3
White bread 30 72 14.6 0.4 2.2
Butter 120 928 0.7 99.8 0.8
Whole milk 750 491 36 26.3 24.8
Sweet
Strawberry jam 50 147 35.8 0.1 0.1
Hazelnut spread 40 218 21.6 12.8 2.8
Honey 40 123 30 0 0.1
Sugar 24 98 24 0 0
Fruit curd 125 140 19.3 3.3 7.7
Vanilla pudding 125 134 20.8 3.8 3.5
Strawberry milk 200 167 18.2 6.8 7.4
Banana 179 168 38.3 0.4 2
Apple 195 104 22.2 1.2 0.6
Pear 140 78 17.4 0.4 0.7
Orange 180 72 15 0.4 1.8
Tangerine 80 35 8.2 0 0.5
Orange juice 400 173 36 1 4
Savory
Poultry sausage 40 74 0.1 4.3 8.3
Cervelat sausage 34 120 0.1 10.2 6.1
Sliced cheese 100 374 0 29.2 25.5
Cream cheese (natural) 33 87 0.6 7.8 3
Cream cheese (herbs) 40 124 1 11.6 3.2
Total 3,330 4,562 553 226 123
All values are rounded to the closest decimal.
TABLE 2
Snacks offered in the snack test
Chocolate
cookies
Rice
wafﬂes
Salt
crackers
Energy value
(kcal/100 g) 500 390 486
Carbohydrate (g/100 g) 57.2 63 63
Fat (g/100 g) 26.6 22 22
Protein (g/100 g) 6 8.6 7.8
Nutritional values of the snacks offered to the participants during the
postprandial period. All values are according to the manufacturers’
data (see RESEARCH DESIGN AND METHODS). A glass of still mineral water
was provided along with the cookies.
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signiﬁcantly correlated (r = 0.56; P = 0.012, Pearson’s
coefﬁcient).
The circulating concentrations of glucose, insulin,
C-peptide, and total GLP-1 showed the expected meal-
related increase across conditions (all P , 0.0001 for
time; Fig. 3A–D). Although levels of insulin, C-peptide, and
total GLP-1 were not affected by oxytocin administration
(all P. 0.16), the peak glucose response to breakfast intake
(15 min after meal termination) was reduced by 0.57 mmol/L
after oxytocin compared with placebo administration
(P, 0.02, two-sided t test; Fig. 3A). This difference was still
evident when adjusted for preceding total and carbohydrate-
speciﬁc breakfast intake (both P , 0.03). Total plasma
concentrations of ghrelin were suppressed by breakfast
intake (F2,29 = 31.62, P , 0.0001 for time), without sig-
niﬁcant treatment effects (P . 0.95; Fig. 3E). Conversely,
15 min after breakfast, serum leptin levels were increased
by ;28% compared with preprandial levels (F4,80 = 28.98,
P , 0.0001 for time; Fig. 3F). Leptin concentrations did not
differ between conditions across the whole experimental
period (P . 0.38), although there was a trend toward re-
duced preprandial leptin concentrations after oxytocin
administration (F1,19 = 3.39, P = 0.08 for treatment). Circu-
lating concentrations of growth hormone and active GLP-1
(i.e., the intact form of GLP-1) were likewise comparable
between conditions (all P . 0.14).
DISCUSSION
We demonstrate that oxytocin inhibits food intake and
impacts endocrine regulation in humans. The anorexigenic
effect of oxytocin emerged during the postprandial period,
when reward-driven eating motivation prevails, whereas
energy intake in the fasted state was not affected. Al-
though this pattern could also imply that oxytocin effects
on ingestive behavior emerge with a certain delay, this
TABLE 3
Food intake from the test buffet
Food intake (kcal) Placebo Oxytocin P value
Total 1,180 6 103 1,190 6 105 0.84
Carbohydrates 517 6 41 540 6 41 0.43
Fat 517 6 54 509 6 57 0.84
Protein 145 6 16 142 6 14 0.82
Savory foods 314 6 38 309 6 29 0.91
Sweet foods 233 6 44 206 6 40 0.22
Total food intake, intake of macronutrients, and food intake accord-
ing to taste. Savory and sweet foods contained in the test buffet are
listed separately in Table 1. P values are derived from paired, two-
tailed t tests (n = 20).
FIG. 2. Oxytocin inhibits reward-driven eating and reduces HPA axis activity. A: Mean 6 SEM hunger ratings assessed before (averaged across the
0915- and 0930-h baseline values) and after intranasal administration (vertical dotted line) of oxytocin (24 IU; ● and solid lines) and placebo
(vehicle; ○ and dotted lines). Forty-ﬁve minutes post-treatment, subjects ate from a test breakfast (1000–1030 h) and 100 min thereafter, they
ingested snacks under the pretext of a taste test (1240–1250 h). B: Mean 6 SEM cumulative snack intake (kcal) in the placebo (□) and the
oxytocin condition (■). C: Individual chocolate cookie consumption assessed at the same test in the placebo and the oxytocin condition. Individual
values of both sessions are connected by lines. D–F: Mean 6 SEM concentrations are depicted of plasma ACTH (D), serum cortisol (E), and
norepinephrine (F) assessed before (averaged across the 0915- and 0930-h baseline values) and after oxytocin (● and solid lines) and placebo
(vehicle; ○ and dotted lines) administration. Mean baseline values of both conditions are averaged to a common baseline (n = 20). *P< 0.05, **P<
0.01 for comparisons between conditions (paired t tests).
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assumption is not supported by previous studies indicating
robust central nervous effects of the peptide within 90 min
after administration (3,4,28). Whereas energy expenditure
remained completely unaltered, oxytocin globally attenu-
ated HPA axis activity and blunted the peak glucose re-
sponse to food intake, suggesting an insulin-sensitizing
action of the peptide. These ﬁndings indicate that the
oxytocin system contributes to the control of reward-
related eating as well as of stress axis regulation and
glucose homeostasis in humans.
Oxytocin has been shown in a number of experiments in
rodents to inhibit feeding after intracerebroventricular
injection (6,8). This effect could be mimicked by the pe-
ripheral administration of high oxytocin doses that suppos-
edly trigger hypothalamic oxytocin release in a feed-forward
fashion (7,12). Furthermore, oxytocin receptor antagonists
have been found to acutely hamper the anorexigenic
central nervous impact of hormones such as cholecysto-
kinin and corticotropin-releasing hormone (29,30). Vice
versa, a-melanocyte–stimulating hormone, a crucial player
among the catabolic messengers, triggers oxytocin release
from supraoptic neurons (31). Oxytocin may also induce
a satiating effect by modulating distention signals from the
stomach (32), but in the present experiments, we found no
differences between conditions in postbreakfast hunger
ratings. Considering that the anorexigenic impact of oxy-
tocin selectively concerned the consumption of palatable
snacks, it might rather be speculated that oxytocin acted
on receptors expressed in the brain reward circuit, such as
in the ventral tegmental area (VTA) and nucleus accum-
bens (33,34), that contribute to the regulation of palatable
food intake (19). This conclusion should be corroborated
in more mechanistically orientated experimental ap-
proaches and also in behavioral studies applying effort-
based tests to assess the reward-driven motivation to obtain
palatable food (35).
The attenuating effect of oxytocin on snack intake fo-
cused on chocolate cookies that were preferentially eaten
by our subjects, which underlines the reward-related
component of oxytocin’s anorexigenic impact. Nevertheless,
TABLE 4
Calorie intake and snack ratings during the snack test
Snack type Placebo Oxytocin P value
Intake (kcal) Chocolate
cookies 185 6 41 138 6 38 0.007
Rice wafﬂes 18 6 3 13 6 2 0.15
Salt crackers 81 6 19 75 6 16 0.75
Total 283 6 44 227 6 44 0.03
Palatability Chocolate
cookies 7.7 6 0.28 7.45 6 0.26 0.45
Rice wafﬂes 2.99 6 0.43 3.68 6 0.43 0.05
Salt crackers 7.11 6 0.35 7.31 6 0.29 0.59
Sweetness Chocolate
cookies 8.06 6 0.16 7.87 6 0.25 0.53
Rice wafﬂes 0.95 6 0.24 0.90 6 0.29 0.88
Salt crackers 1.55 6 0.37 1.49 6 0.43 0.83
Saltiness Chocolate
cookies 0.92 6 0.31 0.92 6 0.37 1.00
Rice wafﬂes 1.42 6 0.33 1.68 6 0.43 0.55
Salt crackers 6.25 6 0.44 6.79 6 0.44 0.32
Nutritional values of the snacks are listed in Table 2. P values are
derived from paired, two-tailed t tests (n = 20); bold type indicates
statistical signiﬁcance.
FIG. 3. Plasma glucose and hormones. Mean 6 SEM concentrations of plasma glucose (A), serum insulin (B), serum C-peptide (C), plasma total
GLP-1 (D), plasma total ghrelin (E), and serum leptin (F) assessed before (averaged across the 0915- and 0930-h baseline values) and after
intranasal administration (vertical dotted line) of oxytocin (24 IU; ● and solid lines) and placebo (vehicle; ○ and dotted lines). Subjects ate from
a test breakfast from 1000 to 1030 h and ingested snacks under the pretext of a taste test from 1240 to 1250 h. Mean baseline values of both
conditions are averaged to a common baseline (n = 20). *P < 0.05 for comparisons between conditions (pairwise t tests).
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subjective ratings of chocolate and salty snacks differed in
sweetness and saltiness but not palatability, suggesting
that oxytocin speciﬁcally dampens the motivation to con-
sume sweet-tasting food. In accordance, oxytocin injection
into the VTA in rodents suppresses sucrose intake (36),
and oxytocin signaling is strongly activated by chronic
sucrose ingestion (37), whereas oxytocin-knockout ani-
mals display a preference for sucrose and carbohydrates
with sweet taste (38). Oxytocin did not affect the rated
palatability of chocolate cookies, which might be taken as
an indication that it acted on dopaminergic pathways
responding to the incentive salience of food rather than
opioidergic/cannabinoid signaling assumed to process the
palatability of ingested nutrients (39). Tests of olfactory
function indicated that the decrease in snack intake was
not mediated by effects on sensory processing. Further-
more, biasing effects on ingestive behavior related to de-
mand characteristics and social desirability were excluded
by interviews conﬁrming unawareness of food intake
measurements and by ratings of the perceived trustwor-
thiness of the experimenter. From a clinical perspective,
the conclusion that oxytocin acts on reward-processing
brain circuits to suppress snack intake is in line with
observations in patients with Prader-Willi syndrome, who
suffer from hyperphagic obesity due to insatiable food
craving and have been reported to display a 40% reduction
in the number and size of oxytocin neurons (40).
The oxytocin-triggered decrease in ACTH, cortisol, and
norepinephrine concentrations in the basal and post-
prandial state extends and reﬁnes previous ﬁndings of an
attenuating impact of intravenous oxytocin on basal cor-
ticotropic function (41) and of intranasal oxytocin on HPA
axis activity in response to social and physical stress
(42,43) and supports the assumption that the suppression
of HPA axis activity by oxytocin is mediated not only by
adrenal (44) but also by central mechanisms. Acute and
chronic activation of endocrine stress axes favors the in-
take of “comfort food” (i.e., highly palatable food) (45). In
a negative feedback loop, activation of central nervous
reward circuits by consuming sucrose reduces stress-
induced HPA axis activity (46). The intake of sugar com-
pared with an equicaloric fat solution induces a selective,
twofold increase in hypothalamic oxytocinergic neuronal
activity, whereas central nervous oxytocin receptor an-
tagonism triggers the intake of sucrose but not fat (47).
Oxytocin might impact the cross talk between reward- and
stress-related pathways by modulating VTA and nucleus
accumbens dopamine signaling (48) known to facilitate
stress-induced HPA axis activity (49). The conclusion that
the inhibition of palatable snack intake by oxytocin
involves a stress axis-related component (43) is supported
by the positive association between the attenuating effects
of oxytocin on cortisol concentrations and chocolate
cookie intake.
In addition to its dampening effect on HPA axis activity,
oxytocin administration blunted the peak plasma glucose
response to breakfast intake. Total calorie and macronu-
trient uptake from the breakfast buffet were closely com-
parable in both conditions, and moreover, the reduction in
blood glucose concentrations was still evident after cor-
recting the data for slight differences in these parameters.
Considering that the circulating concentrations of insulin,
C-peptide, and both total and active GLP-1, an incretin hor-
mone with insulin-secretory properties, were not affected by
oxytocin, this ﬁnding suggests a subtle but discernible im-
provement in insulin sensitivity after administration of the
peptide. Although this conclusion is in need of corrobo-
ration in experiments focusing on glucose homeostasis, it
is in line with ﬁndings that oxytocin enhances insulin
sensitivity and glucose tolerance in a rodent model of diet-
induced obesity independent of its effects on body weight
(7,50).
We found no effect of acute oxytocin administration on
fasting and postprandial energy expenditure as assessed
by indirect calorimetry. In diet-induced obese rats losing
weight due to chronic oxytocin administration, the de-
crease in energy expenditure normally associated with
weight loss was prevented by oxytocin treatment, proba-
bly via effects on hypothalamic thermoregulation (7). Vice
versa, the ablation of oxytocin neurons favors the de-
velopment of obesity by reducing energy expenditure (9).
Against this background, our ﬁnding suggests that rather
than exerting acute effects, oxytocin contributes to the
regulation of energy expenditure on a long-term basis.
Also in our experiments, oxytocin did not affect the cir-
culating concentrations of ghrelin and GLP-1 and induced
merely nonsigniﬁcant changes in leptin, hormones known
to affect energy expenditure and energy homeostasis (51).
Although intranasal oxytocin administration has been
previously found to increase plasma concentrations of the
peptide (2), this pattern moreover argues against a pe-
ripheral mediation of the observed changes in ingestive
behavior.
In sum, our study provides evidence for a signiﬁcant
contribution of oxytocin to the control of reward-related
eating behavior as well as endocrine regulation in humans.
Further experiments should elucidate the preconditions
and ramiﬁcations of the anorexigenic effects of oxytocin in
humans by exploring the composition and timing of meals
as well as the regulation of satiety in dependence of oxy-
tocin administration. Considering recent ﬁndings that
oxytocin modulates VTA activation in response to cues
predicting social reward and punishment (52), its impact
on the brain reward system might represent a common
denominator of its psychosocial and anorexigenic prop-
erties. In concert with the dampening of stress axis activ-
ity, these effects might, for example, optimize maternal
behavior during breast-feeding by isolating the mother
from distracting food stimuli and preventing stress-induced
inhibition of lactation (53). Excessive reward-driven food
intake, chronic HPA axis activation, and insulin re-
sistance are key factors in the pathogenesis and mainte-
nance of obesity. With most recent clinical pilot data
pointing to weight-loss inducing properties of long-term
intranasal oxytocin administration in obese humans (54),
the potential application of oxytocin in the treatment of
metabolic disorders deserves particular attention in future
research.
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